2025
Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.
Mar N, Petrylak D, Hoimes C, Rosenberg J, Flaig T, Gourdin T, Barata P, Henry E, Bilen M, George S, Rao S, Assikis V, Burgess E, Lewis B, Srinivas S, Gorla S, Meng C, Zhu Y, O'Donnell P. Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results. Journal Of Clinical Oncology 2025, 43: 4583-4583. DOI: 10.1200/jco.2025.43.16_suppl.4583.Peer-Reviewed Original ResearchMedian event-free survivalPathological complete responseEvent-free survivalInvestigator assessmentEnfortumab vedotinEfficacy resultsOS ratesNeoadjuvant treatmentSafety profileFollow-upPathologic complete response ratePelvic lymph node dissectionEvent-free survival rateAntitumor activityLong-term follow-upCentral pathology reviewEstimated OS ratesNeoadjuvant treatment optionsLymph node dissectionMedian Follow-UpPhase 3 trialCT2-T4aN0M0Median OSConsistent with prior reportsComplete responseMP07-09 LACK OF SURVIVAL BENEFIT OF PELVIC LYMPH NODE DISSECTION FOR RADICAL PROSTATECTOMY PATIENTS WHO UNDERWENT RADIOTHERAPY
Kim I, Brito J, Renzulli J, Sprenkle P, Leapman M, Kim I. MP07-09 LACK OF SURVIVAL BENEFIT OF PELVIC LYMPH NODE DISSECTION FOR RADICAL PROSTATECTOMY PATIENTS WHO UNDERWENT RADIOTHERAPY. Journal Of Urology 2025, 213: e234. DOI: 10.1097/01.ju.0001109784.58660.a5.09.Peer-Reviewed Original ResearchBenefit of pelvic lymph node dissectionLymph node dissectionNode dissectionPatients WHOPatientsDissectionEvaluating clinical and pathologic predictors for pathologic lymph node positivity (pN+) in patients with clinical T1-4N0M0 bladder cancer undergoing cystectomy.
Jaime-Casas S, Barragan-Carrillo R, Zugman M, Zang P, Ebrahimi H, Castro D, Mercier B, Li X, Dizman N, Salgia N, Hsu J, Nguyen C, Yip W, Chehrazi-Raffle A, Zengin Z, Meza L, Pal S, Tripathi A. Evaluating clinical and pathologic predictors for pathologic lymph node positivity (pN+) in patients with clinical T1-4N0M0 bladder cancer undergoing cystectomy. Journal Of Clinical Oncology 2025, 43: 877-877. DOI: 10.1200/jco.2025.43.5_suppl.877.Peer-Reviewed Original ResearchConcomitant carcinoma in situRecurrence-free survivalPositive surgical marginsLymph node positivityRadical cystectomyLymphovascular invasionOverall survivalPreoperative hydronephrosisSurgical marginsPathologic predictorsBladder cancerPredictors of lymph node positivityConcomitant CISMultivariate analysisPathologic lymph node positivityPelvic lymph node dissectionPathological lymph node involvementMultivariate Cox proportional hazards modelMultivariate Cox regression modelNode-positiveBladder-preserving approachPreoperative renal functionLymph node dissectionLymph node involvementCarcinoma in situEvaluating the therapeutic role of lymph node dissection in variant histology bladder cancer.
Rahman S, Hesse D, Jalfon M, Kong V, Ghali F. Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer. Journal Of Clinical Oncology 2025, 43: 749-749. DOI: 10.1200/jco.2025.43.5_suppl.749.Peer-Reviewed Original ResearchLymph node dissectionVariant histology bladder cancerRadical cystectomyBladder cancerNodal dissectionNode dissectionSurvival benefit of lymph node dissectionAssociated with lymph node dissectionBenefit of lymph node dissectionImpact of lymph node dissectionLymph node dissection statusPathological nodal statusCox proportional hazards analysisNational Cancer DatabaseUrothelial bladder cancerKaplan Meier analysisCox proportional hazards regressionProportional hazards analysisProportional hazards regressionNo-LND groupDegree of therapeutic benefitNeuroendocrine subtypeSarcomatoid histologyT3/4 diseaseUC histology
2024
Clinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation
Shalaby A, Jan I, Ohri N, Yehia Z, Toppmeyer D, Haffty B. Clinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e331-e332. DOI: 10.1016/j.ijrobp.2024.07.731.Peer-Reviewed Original ResearchBreast-conserving surgeryPALB2 variantsBreast cancer patientsInterpretations of pathogenicityClinical outcomesPathogenic variantsHYPO-RTBreast cancer patients treated with radiationCancer patients treated with radiationCancer patientsRisk of radiation toxicitySentinel lymph node dissectionPatients treated with radiationMedical recordsPALB2 pathogenic variantsContralateral breast cancerExternal beam radiationMedian tumor sizeLymph node dissectionSuppression of cancer developmentGrade 2 fibrosisRecurrence 4 monthsMultigene panel testingDNA double-strand break repairDouble-strand break repairThe Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Wang L, Zhang Y, Ausat N, Hernandez M, Rosenthal D, Garden A, Ferrarotto R, Gunn G, Fuller C, Phan J, Morrison W, Lee A, Moreno A, Gross N, Spiotto M, Frank S. The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma (OPSCC). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s123-s124. DOI: 10.1016/j.ijrobp.2024.07.223.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaIntensity modulated proton therapyDNA scoreConcurrent chemoradiationTreatment failureNode dissectionInduction chemotherapyHuman papillomavirusHPV+ oropharyngeal squamous cell carcinomaHigh risk of treatment failurePhase III randomized trialRisk of treatment failureMulticenter phase III randomized trialPost-induction chemotherapyTreatment de-escalationHuman papillomavirus DNALymph node dissectionPhase III trialsSquamous cell carcinomaPotential of TFAJCC-7RT doseTumor controlTreatment toxicityPost-RTPhase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).
Frank S, Busse P, Rosenthal D, Hernandez M, Swanson D, Garden A, Sturgis E, Ferrarotto R, Gunn G, Patel S, LEE N, Lin A, Snider J, McDonald M, Henson C, Bajaj G, Kalman N, Parvathaneni U, Katz S, Foote R. Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC). Journal Of Clinical Oncology 2024, 42: 6006-6006. DOI: 10.1200/jco.2024.42.16_suppl.6006.Peer-Reviewed Original ResearchProgression-free survivalProgression-free survival HROverall survivalOropharyngeal carcinomaInduction chemotherapyChemoradiation therapyGastrostomy-tube dependenceHazard ratioRate of progression-free survivalManagement of head and neck tumorsIntensity-modulated photon therapyReceipt of induction chemotherapyTreated with chemoradiation therapyIntensity-modulated proton therapySurgical lymph node dissectionHead and neck tumorsPhase III randomized trialWeight loss <5%Bilateral neck treatmentHuman papillomavirus statusLymph node dissectionTarget tumor volumeMedian Follow-UpDe-intensification strategiesIntent-to-treatStudy EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H.
O'Donnell P, Hoimes C, Rosenberg J, Petrylak D, Mar N, Barata P, Srinivas S, Gourdin T, Henry E, Bilen M, George S, Rao S, Assikis V, Burgess E, Lewis B, Bowman I, Brancato S, Mildiner-Earley S, Zhu Y, Flaig T. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H. Journal Of Clinical Oncology 2024, 42: 4564-4564. DOI: 10.1200/jco.2024.42.16_suppl.4564.Peer-Reviewed Original ResearchPathological complete responsePathologic complete response ratePathological downstaging ratePathological downstagingEnfortumab vedotinEV treatmentUrothelial cancerPelvic lymph node dissectionAntitumor activityCisplatin-ineligible patientsNeoadjuvant treatment optionsPhase 1b/2 studyCentral pathology reviewMetastatic urothelial cancerLymph node dissectionEvent-free survivalCancer-related therapyAntibody-drug conjugatesStage cT2Improved OSComplete responseECOG PSNeoadjuvant treatmentCisplatin-ineligibleNode dissectionAssociation between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy
Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.Peer-Reviewed Original ResearchPelvic lymph node dissectionBenefit of pelvic lymph node dissectionGleason grade groupLymph node dissectionProstate cancer patientsRadical prostatectomyNode dissectionProstate cancer treated with radical prostatectomyCancer patientsAssociated with improved OSTime of radical prostatectomyGrade groupSurvival of prostate cancer patientsMedian PSA valuePre-operative characteristicsProstate cancer-specificTime of RPLog-rank testKaplan-Meier curvesPSA valuesSurvival benefitProstate cancerMedian ageClinical benefitCancer-Specific
2023
Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
Myers A, Briganti A, Leibovich B, Lerner S, Moschini M, Rouprêt M, Shariat S, Spiess P, Stenzl A, Taneja S, Touijer K, Kamat A. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? European Urology Oncology 2023, 7: 412-420. PMID: 37980250, DOI: 10.1016/j.euo.2023.10.028.Peer-Reviewed Original ResearchLymph node dissectionNode dissectionPatient selectionGenitourinary cancersCurrent evidencePathologic nodal stageJudicious patient selectionAdjuvant treatmentNodal stageCollaborative reviewGenitourinary malignanciesTestis cancerTherapeutic benefitDissectionCancerLymphadenectomyLymphHighlight knowledge gapsReference standardContemporary evidenceOngoing areaCumulative benefitsEvidenceSurgeryPenileSurgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities
AlAshqar A, Ghazarian M, Webster E, Upadhyay A, Azodi M, Schwartz P, Ratner E, Altwerger G. Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities. Gynecologic Oncology Reports 2023, 49: 101240. PMID: 37636496, PMCID: PMC10450407, DOI: 10.1016/j.gore.2023.101240.Peer-Reviewed Original ResearchEndometrioid endometrial cancerOldest-old womenOncologic outcomesEndometrial cancerOlder womenComorbidity statusEarly-stage endometrioid endometrial cancerKaplan-Meier survival analysisLymph node dissectionRetrospective cohort studyFive-year survivalTimes higher riskCounseling of patientsComorbidity burdenPreoperative optimizationComorbidity indexNode dissectionCohort studyIndependent predictorsMedian agePostoperative infectionSurgical treatmentRisk diseaseSurgical managementWomen 80Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
Flaig T, Rosenberg J, Hoimes C, O'Donnell P, Mar N, Gourdin T, Henry S, Bilen M, George S, Barata P, Srinivas S, Rao S, Assikis V, Burgess E, Ramamurthy C, Haas G, Lukas J, Mildiner-Earley S, Yu Y, Petrylak D. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. Journal Of Clinical Oncology 2023, 41: 4595-4595. DOI: 10.1200/jco.2023.41.16_suppl.4595.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerEvent-free survivalPhase 1b/2 studyPathological complete responseCancer-related therapyEV treatmentUrothelial cancerSafety profilePD-1/L1 inhibitorsMedian event-free survivalPelvic lymph node dissectionAdvanced urothelial cancerAntitumor activityCisplatin-ineligible patientsManageable safety profileNeoadjuvant treatment optionsOngoing phase 2Pathological downstaging ratePts underwent surgeryTolerable safety profileCentral pathology reviewKey secondary endpointLymph node dissectionPhase 3 studyInvasive bladder cancerClinical Benefits of Lobe-Specific Lymph Node Dissection in Surgery for NSCLC: A Systematic Review and Meta-Analysis
Woo W, Shin J, Kipkorir V, Yang Y, Lee S, Lee C. Clinical Benefits of Lobe-Specific Lymph Node Dissection in Surgery for NSCLC: A Systematic Review and Meta-Analysis. JTO Clinical And Research Reports 2023, 4: 100516. PMID: 37214413, PMCID: PMC10199215, DOI: 10.1016/j.jtocrr.2023.100516.Peer-Reviewed Original ResearchLymph node dissectionLobe-specific lymph node dissectionRecurrence-free survivalPostoperative complicationsNode dissectionQuality of evidenceS-LNDSystematic lymph node dissectionRisk of postoperative pneumoniaRate of postoperative complicationsRates of chylothoraxCompare clinical outcomesLong-term prognosisHeterogeneous study populationsRandomized Controlled TrialsCurative resectionRisk of biasOverall survivalPostoperative pneumoniaClinical benefitRetrospective studyClinical outcomesLung cancerPrimary outcomeSecondary outcomes
2022
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates
Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.Peer-Reviewed Original ResearchStandard pelvic lymph node dissectionPelvic lymph node dissectionLymph node dissectionNode-positive patientsNode dissectionAdjuvant treatmentRecurrence rateGleason scoreSubgroup analysisNational Comprehensive Cancer Network guidelinesPSA progression-free survivalAdjuvant androgen deprivation therapyPSA recurrence rateAndrogen deprivation therapyNode-positive diseaseProgression-free survivalGleason score 8Kaplan-Meier analysisAdditional therapeutic benefitBiochemical recurrence ratePositive prostate cancerGleason score 6Time of prostatectomyDeprivation therapyMedian followUnmeasured factors are associated with the use of completion lymph node dissection (CLND) in melanoma
Leonard L, Beaty L, Thomas M, Quinn C, Colborn K, de Araujo T, Torphy R, Assumpção L, Olino K, Studts C, Franco S, McCarter M, Stewart C, Gleisner A. Unmeasured factors are associated with the use of completion lymph node dissection (CLND) in melanoma. Journal Of Surgical Oncology 2022, 127: 716-726. PMID: 36453464, DOI: 10.1002/jso.27153.Peer-Reviewed Original ResearchConceptsCompletion lymph node dissectionSentinel lymph nodesPositive sentinel lymph nodesLymph node dissectionNode dissectionMultivariable mixed-effects logistic regression modelGovernment-based insuranceNational Cancer DatabasePrimary tumor locationStage III melanomaEffect of patientContribution of patientMixed effects logistic regression modelsLogistic regression modelsTumor factorsOlder patientsSurvival benefitLymph nodesSurgical excisionStandard treatmentTumor locationCancer DatabasePatient variablesPatientsLower limbsStudy EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.
Petrylak D, Flaig T, Mar N, Gourdin T, Srinivas S, Rosenberg J, Guseva M, Yu Y, Narayanan S, Hoimes C. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. Journal Of Clinical Oncology 2022, 40: 4582-4582. DOI: 10.1200/jco.2022.40.16_suppl.4582.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerTreatment-related adverse eventsUrothelial cancerNeoadjuvant therapyAdverse eventsBladder cancerUnmet needPathological complete response ratePelvic lymph node dissectionEffective neoadjuvant therapyOngoing phase 2Pathological downstaging ratePhase 1b/2 trialComplete response rateKey secondary endpointLymph node dissectionMuscle-invasive diseaseRisk of progressionInvasive bladder cancerStandard of careHigh unmet needPhase 2Antibody-drug conjugatesCancer ptsCT4 tumorsComparison of perioperative complications for extended vs standard pelvic lymph node dissection in patients undergoing radical prostatectomy for prostate cancer: a meta-analysis.
Kong J, Lichtbroun B, Sterling J, Wang Y, Wang Q, Singer EA, Jang TL, Ghodoussipour S, Kim IY. Comparison of perioperative complications for extended vs standard pelvic lymph node dissection in patients undergoing radical prostatectomy for prostate cancer: a meta-analysis. American Journal Of Clinical And Experimental Urology 2022, 10: 73-81. PMID: 35528467, PMCID: PMC9077149.Peer-Reviewed Original ResearchPelvic lymph node dissectionLymph node dissectionRadical prostatectomyPerioperative complicationsRandom-effects modelProstate cancerSurgery subgroupNode dissectionComplication rateRisk ratioSubgroup analysisStandard pelvic lymph node dissectionTime of RPRobotic approachCochrane LibraryComplicationsSPLNDGreater riskPatientsAvailable evidencePooled dataAdditional studiesCancerSignificant differencesProstatectomyEvidence-Based Clinical Practice Guidelines for Extramammary Paget Disease
Kibbi N, Owen J, Worley B, Wang J, Harikumar V, Downing M, Aasi S, Aung P, Barker C, Bolotin D, Bordeaux J, Cartee T, Chandra S, Cho N, Choi J, Chung K, Cliby W, Dorigo O, Eisen D, Fujisawa Y, Golda N, Halfdanarson T, Iavazzo C, Jiang S, Kanitakis J, Khan A, Kim J, Kuzel T, Lawrence N, Leitao M, MacLean A, Maher I, Mittal B, Nehal K, Ozog D, Pettaway C, Ross J, Rossi A, Servaes S, Solomon M, Thomas V, Tolia M, Voelzke B, Waldman A, Wong M, Zhou Y, Arai N, Brackett A, Ibrahim S, Kang B, Poon E, Alam M. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology 2022, 8: 618-628. PMID: 35050310, DOI: 10.1001/jamaoncol.2021.7148.Peer-Reviewed Original ResearchConceptsExtramammary Paget's diseaseSecondary extramammary Paget's diseaseClinical practice guidelinesNonsurgical treatmentPaget's diseaseMalignant neoplasmsPractice guidelinesEvidence-based clinical practice guidelinesInvasive extramammary Paget's diseaseCarbon dioxide laser therapyClinical care recommendationsInternal malignant neoplasmsMultiple skin biopsiesDistant metastatic diseaseLymph node dissectionHigh-risk tumorsCare of adultsSuperior management approachCurative intentNode dissectionProspective registryMetastatic diseaseSentinel lymphSurgical resectionTumor characteristicsStudy EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
Petrylak D, Flaig T, Mar N, Gourdin T, Srinivas S, Rosenberg J, Guseva M, Yu Y, Narayanan S, Hoimes C. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. Journal Of Clinical Oncology 2022, 40: 435-435. DOI: 10.1200/jco.2022.40.6_suppl.435.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerTreatment-related adverse eventsUrothelial cancerNeoadjuvant therapyAdverse eventsUnmet needPathological complete response ratePelvic lymph node dissectionEffective neoadjuvant therapyPathological downstaging ratePhase 1b/2 trialComplete response rateKey secondary endpointLymph node dissectionCentral pathology reviewMuscle-invasive diseaseOngoing phase IIRisk of progressionInvasive bladder cancerStandard of careHigh unmet needPhase IIAntibody-drug conjugatesCancer ptsCT4 tumorsStudy EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).
Hoimes C, Flaig T, Srinivas S, Mar N, Petrylak D, O'Donnell P, Bilen M, Sasse C, Yu Y, Birrenkott M, Rosenberg J. Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress). Journal Of Clinical Oncology 2022, 40: tps587-tps587. DOI: 10.1200/jco.2022.40.6_suppl.tps587.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerMetastatic urothelial carcinomaCentral pathology reviewPerioperative therapyPathology reviewMicrotubule-disrupting agent monomethyl auristatin EPathological complete response ratePelvic lymph node dissectionBlinded independent central reviewPathological downstaging rateTolerable safety profileComplete response rateOverall survival benefitDisease-free survivalEvent-free survivalHigh-risk featuresLymph node dissectionPhase 3 studyPD-L1 inhibitorsInvasive bladder cancerIndependent central reviewPlatinum-based therapyMonomethyl auristatin ECurrent standardAntibody-drug conjugates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply